A 47-year-old patient sits across from me with a notebook full of numbers. She has lost the same fifteen pounds three separate times in the last six years. Each time she rebounded back to within two or three pounds of the starting weight within a year. She is not a person who lacks discipline — she ran a half-marathon last spring and tracks her food meticulously. Her question is simple and the right one: why does my body keep returning to the same number?
The honest answer is that her body has a defended weight, and the defenses are biological, not behavioral. Set-point theory is the framework that describes those defenses. It has been around for forty years, but the 2026 version of the conversation looks different than the 2015 version because we now have tools — GLP-1 receptor agonists in particular — that actually shift the defended weight rather than fight it. That changes the clinical conversation in important ways.
What set-point theory actually says
The body regulates fat mass the same way it regulates body temperature, blood glucose, or blood pressure — through a homeostatic feedback loop. When fat mass drops below the defended level, the body responds with a coordinated set of adaptations designed to restore it. Leptin, the hormone produced by adipose tissue that signals satiety to the hypothalamus, drops in proportion to fat loss. The hypothalamus interprets the drop as a famine signal and turns on a series of conservation responses.
Resting metabolic rate declines beyond what fat-free mass loss alone predicts — the metabolic adaptation. Thyroid output shifts toward more reverse T3, which is metabolically inactive. Sympathetic nervous system tone decreases, lowering non-exercise activity thermogenesis (the calories you burn fidgeting, standing, walking around). Hunger hormones — ghrelin in particular — rise. Satiety signals decline. The drive to eat becomes more compelling and harder to override with willpower.
This is not a defect. It is the same machinery that kept our ancestors alive through seasonal food scarcity. It is also the machinery that has produced the regain pattern in the patient I just described, and in the majority of patients I see for medical weight loss.
The defended weight itself is not fixed. It drifts upward over years in response to a chronic obesogenic environment — ultra-processed food, chronic inflammation, sleep deprivation, hormonal decline, certain medications. Once it has drifted upward, the same homeostatic machinery defends the new, higher weight just as vigorously as it once defended a lower one. Weight loss without addressing what shifted the set-point upward in the first place produces the regain pattern.
What changed in 2026: the GLP-1 conversation
GLP-1 receptor agonists — semaglutide, tirzepatide, and the newer agents in the pipeline — do something that diet and exercise alone cannot do at scale. They appear to lower the defended weight rather than fight against it. The mechanism is partially understood. GLP-1 receptors are expressed in the hypothalamus, particularly in the arcuate nucleus where leptin and other adiposity signals are integrated. Activating those receptors shifts the homeostatic setpoint downward. Patients on therapy do not feel the famine signal in the way they would during equivalent caloric restriction without medication.
Average weight loss in trial populations is roughly 15 percent of body weight on semaglutide over 68 weeks and roughly 21 percent on tirzepatide. In my practice the numbers track reasonably well with the trial data, with substantial individual variation. The variation is what the workup is for.
But the medication is not magic, and the patients who do best on it are the ones whose program addresses the other drivers of the elevated set-point in parallel. Insulin resistance, sex hormone decline, thyroid dysfunction, cortisol dysregulation, and chronic sleep disruption all contribute to where the set-point sits. Treating only the appetite axis while leaving the rest of the system unaddressed produces meaningful loss but a fragile result. When the medication comes off — for any reason, planned or unplanned — the un-addressed drivers will pull the set-point back upward.
The mechanism behind mid-life set-point drift
When I evaluate a patient in their forties or fifties for weight that will not respond to conventional approaches, I am almost always looking at the same cluster:
Insulin resistance is usually present, often with normal fasting glucose and HbA1c. Fasting insulin is the marker that reveals it, and it is rarely on a standard primary care panel. Elevated insulin keeps the body in fat-storage mode regardless of caloric intake, which is part of why caloric restriction alone underperforms in this population.
Sex hormones are usually shifting. In women, estradiol decline reduces insulin sensitivity, redistributes fat from subcutaneous to visceral depots, and changes appetite regulation. Progesterone decline disrupts sleep, which feeds back into the metabolic picture. In men, testosterone decline reduces lean mass — the primary site of insulin-mediated glucose disposal — and increases visceral adiposity directly.
Thyroid output is often subclinically suboptimal. TSH within the lab "normal" range is not the same as a thyroid that is actually producing enough free T3 to support a normal metabolic rate. The reference ranges were built on populations that included substantial undiagnosed thyroid dysfunction; functional optimization sits in a tighter window.
Cortisol matters more in some patients than others. Chronic elevation drives gluconeogenesis, antagonizes insulin at the receptor, promotes visceral fat deposition, and suppresses the conversion of T4 to active T3. The patients who tell me they feel wired and exhausted at the same time, who have trouble falling asleep but wake at 4 a.m. with their mind racing, usually have a cortisol pattern worth measuring.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Sleep architecture is the one most patients underestimate. A single night restricted to four to five hours produces measurable insulin resistance the following day. Chronic disruption of slow-wave sleep — through sleep apnea in particular, which is more common with hormonal decline and weight gain — produces sustained metabolic impairment that no medication will fully overcome.
Each of these contributes to where the set-point sits. A real plan addresses the cluster, not just the appetite axis.
Who is a candidate for GLP-1 therapy — and who is not
Within the medical weight loss program, candidacy for GLP-1 therapy is a specific clinical decision, not a default. The patients who tend to respond well share several features: insulin resistance documented on labs, central adiposity, at least one adjacent driver that can be addressed in parallel, and realistic expectations about timeline.
The patients who I do not start on GLP-1 include those with personal or family history of medullary thyroid carcinoma or MEN2 syndrome, prior pancreatitis, certain GI motility disorders, and patients whose body composition does not actually support the weight loss target — including some patients with athletic body composition who would lose meaningful muscle mass to reach an arbitrary BMI number.
Patients who are not candidates for GLP-1 are not stuck. The full program includes hormone optimization, thyroid support where labs warrant it, structured nutritional counseling, and resistance training guidance. The set-point can be lowered through other levers; it just takes a different combination.
How I evaluate a patient at the first visit
The first weight loss consultation is not where I write a prescription. It is where I gather what is needed to actually make a recommendation. I want the prior weight loss attempts in detail — what was tried, for how long, what worked, what failed, and where the regain happened. I want current sleep duration and quality, current stress baseline, current medications and supplements, family history of metabolic disease. I want the goals — both the target outcome and what the patient is and is not willing to do to get there.
Lab work is ordered at that visit if recent results are not available. The panel is comprehensive: fasting insulin, HbA1c, fasting glucose, comprehensive metabolic panel, lipid panel with particle data when warranted, full sex hormone panel, full thyroid panel including reverse T3 and antibodies, cortisol pattern when the symptom picture suggests it, vitamin D, ferritin, hs-CRP. The weight loss assessment tool can give us a starting frame before the visit.
The second visit is the lab review. We sit down with the data and build the plan from what is actually present in the patient's physiology, not from an off-the-shelf protocol.
What the 90-day structured phase looks like
The first 30 days are diagnostic clarity and initial protocol implementation. If GLP-1 is part of the plan, it starts at the lowest dose with a deliberate titration schedule. Adjacent interventions — hormone optimization, thyroid support, nutritional adjustments — are layered in on a schedule the body can absorb without GI overload from too much change at once.
The next 30 days are titration. Dose moves up based on tolerance and response. Body composition is reassessed via DEXA when indicated to confirm the loss is fat, not muscle. This is where I see patients who are not eating enough protein start to lose muscle mass faster than fat mass — a real risk on GLP-1 that needs active management.
The final 30 days are optimization and the maintenance plan. Labs are re-run. Body composition is re-measured. The plan beyond day 90 is built deliberately. Most patients continue with active treatment for longer; some shift toward a lower maintenance dose; a small number complete the program and transition to monitoring only. The decision is made on data, not on a calendar.
The one thing patients consistently underestimate
The set-point does eventually re-set lower with sustained loss, but the timeframe is longer than most patients expect — generally a year or more at the new weight before the homeostatic defenses appear to recalibrate. This is why the post-90-day plan matters more than the initial loss. The patients who lose weight quickly and then disengage from the program almost universally regain. The patients who stay engaged through the recalibration window — including those who continue on a maintenance dose of GLP-1 for that period — are the ones whose loss holds.
That is the framework I want patients to understand before they start. Not as a discouragement, but because the patients who arrive understanding it tend to make better decisions about pacing, expectations, and what success actually looks like at the one-year and two-year marks.
If you have tried weight loss before and watched the same fifteen, twenty, thirty pounds come back, the next step is the metabolic and hormonal workup that should have happened the first time. Bring whatever lab data you have from prior attempts and any prior GLP-1 records. You can book online at either the Columbus clinic or the Warner Robins clinic. The first visit is a real conversation with real data, not a sales pitch for a medication.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.